Page 86 - Haematologica3

J-C. Ianotto et al.
myelofibrosis: a study of the French Groupe
d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM). Br J Haematol. 2009;146(2):223-225.
18. Ianotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol. 2013;162(6):783-791.
19. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essen- tial thrombocythemia and polycythemia vera. Blood. 2006;108(6):1865–1867.
20. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnostic myeloid meta- plasia: a report on 195 cases with a new scor- ing system. Blood. 1996;88(3):1013-1018.
21. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
22. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
23. Barosi G, Zhang MJ, Gale PR. Does ruxoli-
tinib improve survival of persons with MPN-associated myelofibrosis? Should-it? Leukemia. 2014;28(11): 2267-2270.
24. Martí-Carvajal AJ, Anand V, Solà I. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev. 2015;(4):CD010298.
25. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012; 119(11): 2657-2664.
26. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell trans- plantation for patients with primary myelofibrosis: a cohort analysis from the center for international Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2014;20(1):89-97.
27. Pigneux A, Tanguy ML, Michallet M, et al; Société Française de Greffe de Moelle. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol. 2002;116(1):193- 201.
28. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interfer- on alpha-2a. Blood. 2006;108(6):2037-2040.
29. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces com-
plete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065-3072.
30. Masarova L, Patel KP, Newberry KJ, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or poly- cythaemia vera: a post-hoc, median 83 months follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4(4):e165-e175.
31. Silver RT, Barel AC, Lascu E, et al. The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017;123(14): 2680–2687.
32. Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interfer- on-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126(24):2585-2591.
33. Rotunno G, Pacilli A, Artusi V, et al. Epidemiology and clinical relevance of mutations in post polycythemia vera and post essential thrombocythemia myelofi- brosis: a study on 359 patients of the AGIMM group. Am J Hematol. 2016;91(7): 681-686.
34. Pizzi M, Silver RT, Barel A, Orazi A. Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015;28(10):1315- 1323.
446
haematologica | 2018; 103(3)